203787-91-1
203787-91-1
Chemical Structure
Salcaprozate sodium
Synonym(s): SNAC
- CAS No.: 203787-91-1
- Formula:C15H20NNaO4
- Molecular Weight:301.32
IUPAC Name: sodium 8-(2-hydroxybenzamido)octanoate
InChIKey: UOENJXXSKABLJL-UHFFFAOYSA-M
SMILES: O=C(O[Na])CCCCCCCNC(C1=CC=CC=C1O)=O
Biological Activity: Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Salcaprozate sodium | 99.94% | Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salcaprozate sodium (Standard) | 99.91% | Salcaprozate (sodium) (Standard) is the analytical standard of Salcaprozate (sodium). This product is intended for research and analytical applications. Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salcaprozate-d4 sodium | 99.72% | Salcaprozate-d4 (sodium) is a deuterated labeled Salcaprozate (sodium). Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Riley MGI, et, al. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol. Jul-Aug 2009; 28(4):278-93. [Content Brief]
- [2]. Twarog C, et, al. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C 10). Pharmaceutics. 2019 Feb 13; 11(2):78. [Content Brief]
